KMTS
Kestra Medical·NASDAQ
--
--(--)
--
--(--)
KMTS fundamentals
During Q3 2026, Kestra Medical (KMTS) reported revenue of 24.55M, a YoY change of 62.70%. Net income was -34.17M, a YoY change of -57.02%. Click to view the full income statement and explore the company's earnings performance.
Income Statement
Q1,2021 | Q1,2022 | Q3,2024 | Q4,2024 | Q1,2025 | Q2,2025 | Q3,2025 | Q4,2025 | Q1,2026 | Q2,2026 | Q3,2026 | TTM |
|---|
Start Date | May 1, 2020 | May 1, 2021 | Nov 1, 2023 | Feb 1, 2024 | May 1, 2024 | Aug 1, 2024 | Nov 1, 2024 | Feb 1, 2025 | May 1, 2025 | Aug 1, 2025 | Nov 1, 2025 | -- |
End Date | Jul 31, 2020 | Jul 31, 2021 | Jan 31, 2024 | Apr 30, 2024 | Jul 31, 2024 | Oct 31, 2024 | Jan 31, 2025 | Apr 30, 2025 | Jul 31, 2025 | Oct 31, 2025 | Jan 31, 2026 | -- |
Fiscal Year-End | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | Apr 30 | -- |
Revenue | -- -- | -- -- | 8.28M -- | 10.05M -- | 12.78M -- | 14.71M -- | 15.09M +82.31% | 17.23M +71.40% | 19.37M +51.55% | 22.57M +53.40% | 24.55M +62.70% | 83.72M -- |
Sales and Services Revenue | -- -- | -- -- | 8.28M -- | 10.05M -- | 12.78M -- | 14.71M -- | 15.09M +82.31% | 17.23M +71.40% | 19.37M +51.55% | 22.57M +53.40% | 24.55M +62.70% | 83.72M -- |
Cost of Revenue | -- -- | -- -- | 7.40M -- | 8.66M -- | 8.58M -- | 8.88M -- | 8.54M +15.49% | 9.60M +10.89% | 10.52M +22.58% | 11.14M +25.46% | 11.65M +36.32% | 42.91M -- |
Cost of Goods and Services | -- -- | -- -- | 7.40M -- | 8.66M -- | 8.58M -- | 8.88M -- | 8.54M +15.49% | 9.60M +10.89% | 10.52M +22.58% | 11.14M +25.46% | 11.65M +36.32% | 42.91M -- |
Gross Profit | -- -- | -- -- | 880.00K -- | 1.40M -- | 4.20M -- | 5.83M -- | 6.55M +643.98% | 7.63M +446.39% | 8.85M +110.74% | 11.42M +95.95% | 12.91M +97.13% | 40.81M -- |
Operating Expenses | 7.91M -- | 12.29M +55.47% | 20.83M -- | 21.75M -- | 22.63M -- | 24.96M -- | 27.15M +30.36% | 55.84M +156.81% | 37.73M +66.71% | 43.18M +72.97% | 47.67M +75.60% | 184.42M -- |
Selling, General and Administrative Expenses | 1.98M -- | 7.43M +274.50% | 17.09M -- | 17.93M -- | 19.23M -- | 21.45M -- | 23.80M +39.23% | 50.46M +181.50% | 33.73M +75.42% | 38.30M +78.52% | 42.70M +79.45% | 165.19M -- |
Research and Development Expenses | 5.92M -- | 4.86M -17.92% | 3.73M -- | 3.82M -- | 3.40M -- | 3.51M -- | 3.35M -10.23% | 5.39M +40.96% | 4.00M +17.54% | 4.88M +39.01% | 4.97M +48.29% | 19.24M -- |
Operating Income | -7.91M -- | -12.29M -55.47% | -19.95M -- | -20.35M -- | -18.43M -- | -19.13M -- | -20.60M -3.28% | -48.21M -136.93% | -28.88M -56.68% | -31.75M -65.96% | -34.77M -68.75% | -143.61M -- |
Non-Operating Income (Loss) | -- -- | -787.00K -- | -1.66M -- | -1.96M -- | -1.89M -- | -1.48M -- | -1.14M +31.28% | -2.80M -42.56% | 3.08M +263.66% | -996.00K +32.66% | 634.00K +155.61% | -74.00K -- |
Other Non-Operating Income (Loss) | -- -- | 60.00K -- | -8.00K -- | -27.00K -- | -48.00K -- | -40.00K -- | 15.00K +287.50% | -2.69M -9874.07% | 2.83M +5995.83% | -891.00K -2127.50% | 359.00K +2293.33% | -395.00K -- |
Net Interest Expense | -- -- | 847.00K -- | 1.65M -- | 1.94M -- | 1.84M -- | 1.44M -- | 1.16M -30.04% | 104.00K -94.63% | -255.00K -113.88% | 105.00K -92.70% | -275.00K -123.81% | -321.00K -- |
Interest Expense | -- -- | 847.00K -- | 1.65M -- | 1.94M -- | 1.87M -- | 2.32M -- | 1.78M +8.00% | 1.76M -9.04% | 1.91M +2.03% | 1.90M -17.95% | 1.89M +5.89% | 7.46M -- |
Interest Income | -- -- | -- -- | 0 -- | 0 -- | 37.00K -- | 878.00K -- | 628.00K -- | 1.66M -- | 2.17M +5756.76% | 1.80M +104.56% | 2.16M +244.43% | 7.78M -- |
Pretax Income From Continuing Operations | -7.91M -- | -13.08M -65.43% | -21.61M -- | -22.31M -- | -20.32M -- | -20.61M -- | -21.74M -0.63% | -51.01M -128.63% | -25.79M -26.96% | -32.75M -58.89% | -34.13M -56.99% | -143.68M -- |
Income Tax Expense | 47.00K -- | 57.00K +21.28% | 14.00K -- | -27.00K -- | 7.00K -- | 8.00K -- | 18.00K +28.57% | 102.00K +477.78% | 33.00K +371.43% | 34.00K +325.00% | 35.00K +94.44% | 204.00K -- |
Net Income | -7.95M -- | -13.13M -65.17% | -21.62M -- | -22.28M -- | -20.32M -- | -20.62M -- | -21.76M -0.65% | -51.11M -129.36% | -25.83M -27.08% | -32.78M -58.99% | -34.17M -57.02% | -143.89M -- |
Net Income Attributable to Minority Interests | -- -- | -- -- | 0 -- | 0 -- | -439.00K -- | -253.00K -- | -250.00K -- | 942.00K -- | 0 +100.00% | 0 +100.00% | 0 +100.00% | 942.00K -- |
Net Income Attributable to Owners of the Company | -7.95M -- | -13.13M -65.17% | -21.62M -- | -22.28M -- | -19.88M -- | -20.37M -- | -21.51M +0.51% | -52.05M -133.59% | -25.83M -29.88% | -32.78M -60.96% | -34.17M -58.85% | -144.83M -- |
Preferred Stock Dividends | -- -- | -- -- | 1.81M -- | 1.99M -- | 2.38M -- | 3.32M -- | 3.32M +83.44% | 3.29M +65.05% | 0 -100.00% | 0 -100.00% | 0 -100.00% | 3.29M -- |
Net Income Attributable to Common Stockholders | -7.95M -- | -13.13M -65.17% | -23.43M -- | -24.28M -- | -22.27M -- | -23.69M -- | -24.83M -5.98% | -55.34M -127.96% | -25.83M -15.98% | -32.78M -38.39% | -34.17M -37.58% | -148.12M -- |
Total Comprehensive Income | -7.95M -- | -13.13M -65.17% | -21.62M -- | -22.28M -- | -20.32M -- | -20.62M -- | -21.76M -0.65% | -51.11M -129.36% | -25.83M -27.08% | -32.78M -58.99% | -34.17M -57.02% | -143.89M -- |
Total Comprehensive Income Attributable to Minority Interests | -- -- | -- -- | -- -- | -- -- | -- -- | -253.00K -- | -250.00K -- | 942.00K -- | -- -- | 0 +100.00% | 0 +100.00% | -- -- |
Total Comprehensive Income Attributable to Owners of the Company | -7.95M -- | -13.13M -65.17% | -21.62M -- | -22.28M -- | -20.32M -- | -20.37M -- | -21.51M +0.51% | -52.05M -133.59% | -25.83M -27.08% | -32.78M -60.96% | -34.17M -58.85% | -144.83M -- |
Basic EPS | -75 -- | -124 -65.33% | -1.18 -- | -- -- | -1.12 -- | -- -- | -1.25 -5.93% | -1.08 -- | -0.5 +55.36% | -0.64 -- | -0.61 +51.20% | -2.83 -- |
Basic EPS from Continuing Operations | -- -- | -- -- | -1.18 -- | -- -- | -1.12 -- | -1.19 -- | -1.25 -5.93% | -- -- | -0.5 +55.36% | -0.64 +46.22% | -0.61 +51.20% | -- -- |
Diluted EPS | -75 -- | -124 -65.33% | -1.18 -- | -- -- | -1.12 -- | -- -- | -1.25 -5.93% | -- -- | -0.5 +55.36% | -0.64 -- | -0.61 +51.20% | -- -- |
Diluted EPS from Continuing Operations | -- -- | -- -- | -1.18 -- | -- -- | -1.12 -- | -1.19 -- | -1.25 -5.93% | -- -- | -0.5 +55.36% | -0.64 +46.22% | -0.61 +51.20% | -- -- |
You can ask Aime
What guidance did Kestra Medical's management provide for the next earnings period?Did Kestra Medical beat or miss consensus estimates last quarter?What is the revenue and EPS growth rate for Kestra Medical year over year?What were the key takeaways from Kestra Medical’s earnings call?What were the key takeaways from Kestra Medical's earnings call?What factors drove the changes in Kestra Medical's revenue and profit?What is Kestra Medical's gross profit margin?What does Kestra Medical do and what are its main business segments?
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
